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ABSTRACT
Background
Metabolic syndrome (MS) is primarily the consequence of  
excess central adiposity but can also result from low grade 
systemic inflammation inducing insulin resistance. There 
is a global increase in the prevalence of  MS; it is on this 
background that evaluation of  the prevalence of  MS in a 
poor rural farming community with a low expected low 
prevalence of  obesity is relevant. The objective of  this study 
was to determine the prevalence of  metabolic syndrome 
using the National Cholesterol Education Project: Adult 
Treatment Panel III definition (MS-ATP) in a rural 
Nigerian community.
Methods
300 adult consenting participants were bled after an 
overnight fast, and venous blood obtained for lipid studies 
and fasting blood glucose estimation. Measurements were 
made to determine height, weight, waist circumference and 
blood pressure. The prevalence of  each diagnostic 
component was determined and the relative risk (RR) of  
each component for MS-ATP was calculated.
Results
The prevalence of  MS-ATP was 6.30%, central obesity 
5 . 3 3 %  ( R R = 3 . 3 [ 9 5 %  C I : 1 . 0 8 - 1 0 . 2 6 ] ) ,  a n d  
hypertriglyceridaemia 11.33% (RR=21.91[95% CI:8.42-
57.32]). The prevalence of  low HDL-cholesterol was 
highest (85.67%) but the RR was not calculable.
Conclusion
Unlike previous reports the prevalence of  central obesity 
was very low in this study and contributed little to the 
development of  MS-ATP. Hypertriglyceridaemia appears 
to be associated with the greatest risk of  developing 
metabolic syndrome in this community while Low HDL-
cholesterol although most prevalent is a poor diagnostic 
requirement for metabolic syndrome. 





The metabolic syndrome is a cluster of  cardiovascular 
disease risk factors that are metabolic in origin and include 
atherogenic dysl ipidaemia,  hyper tension and 
hyperglycaemia. Its aetiogenesis is thought to be related to 
excess adiposity-mediated insulin resistance. Mediators of  
this adiposity-mediated insulin resistance include physical 
inactivity, genetic factors, advancing age, endocrine 
1-3dysfunction and drugs .
Abdominal (central) obesity is characterized by enlarged 
fat cells as well as increased numbers of  monocyte-derived 
macrophages within adipose tissue. These enlarged 
adipocytes release an excess of  free fatty acid that impairs 
1,4the actions of  insulin in muscle and liver . Enlarged fat 
cells and their surrounding macrophages further produce 
an excess of  adipokines, including leptin and resistin and 
decreased quantities of  adiponectin, together with 
increased amounts of  the adipocytokines, tumour necrosis 
factor-  (TNF- ) and interleukin (IL)-6, each of  which, in 
addition  to free fatty acid, contribute to impaired insulin 
1,4sensitivity . 
In addition to insulin resistance, low-grade systemic 
5-8inflammation  has been strongly implicated in the 
pathophysiology of  the metabolic syndrome. Inactivity is 
9-12associated with insulin resistance  and elevated levels of  
the proinflammatory marker  high-sensitivity C-reactive 
protein (hs-CRP), which is associated with many other 
13metabolic syndrome features . The excessive intake of  
carbohydrates and saturated fats in addition to causing 
obesity were recently reported to directly induce several 
proinflammatory effects, including the increased 
production of  reactive oxygen species, upregulation of  
nuclear factor ß in monocytes and polymorphonuclear 
14cells and CRP production .
A recent meta-analysis of  longitudinal studies revealed that 
the metabolic syndrome was associated with a relative risk 
of  cardiovascular (CV) events and death of  1.54 (95% CI: 
151.32-1.79) after adjustment for traditional CV risk factors .
Reports on community-based prevalence of  MS in Nigeria 
and Sub-Saharan Africa are not common; previous studies 
16have reported MS in a Sub-Saharan African setting , 
17diabetics  and outpatients in family medicine clinics in 
18southern Nigeria . 
The objectives of  this study therefore, are to determine the 
prevalence of  metabolic syndrome as defined by the 
National Cholesterol Education Program Adult Treatment 
Panel III (MS-ATP) and the relative risk of  the MS 
components in adult Nigerians living in the rural 
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community of  Odufor Etche, Rivers State, Nigeria.
MATERIALS AND METHODS
This study was approved by the Research Ethics Committee 
of  the College of  Health Sciences, University of  Port 
Harcourt, Rivers State, Nigeria.
Participants
This study was conducted in the village of  Odufor in Etche 
Local Government Area of  Rivers State, Nigeria. Odufor is a 
small, predominantly farming village with a resident adult 
population of  about 1000.
Three hundred adults excluding pregnant women, 
individuals with obvious ascites and other forms of  oedema, 
as well as non-ambulatory subjects who could not stand for 
weight and height measurements in spite of  previous consent 
to participate were excluded. Participants were educated on 
the goals of  the study and the extent of  their involvement in 
the study. The study population consisted of  140 males and 
160`females. 
Data Collection
The study was conducted between 8.00am and 10 am daily, in 
May/June of  2008. On arrival at the study venue, each 
subject was allowed to rest for 15 minutes, and then a 
pretested questionnaire designed for the study was filled out 
with the help of  a researcher. Personal and family medical 
history of  obesity, hypertension, diabetes mellitus, and renal 
disease was also obtained. The subject's history of  
leisure/voluntary exercise and occupation was used to assess 
his/her level of  physical activity.
Determination of Waist Circumference
Waist circumference of  the subjects was recorded using a 
measuring tape. The iliac crest was first identified by 
palpation and then a measuring tape placed around the waist, 
at the level of  the iliac crest in a horizontal plane, parallel to 
the floor. The tape was snug but did not compress the skin. 
Subjects were asked to inhale and then exhale. The 
measurement was taken at the end of  a normal expiration, in 
19centimeters . 
Measurement of Blood Pressure
Blood pressure was measured using the auscultatory method, 
with the subject sitting upright in a straight-back chair. An 
inf latable 6 inch cuff  attached to a mercury 
sphygmomanometer (Accoson, UK) was wrapped around 
the upper left arm and a stethoscope (Littman, 3M, USA) 
placed over the brachial artery at the elbow. The cuff  pressure 
at which the tapping (Korotkoff) sounds were first heard was 
recorded as the systolic blood pressure and the point at which 
these Korotkoff  sounds disappeared (phase 5) was taken as 
the diastolic pressure. Average blood pressure readings based 
on records on at least two occasions were computed for this 
study.
Serum Glucose and Lipid Estimations
Patients were asked to fast overnight prior to presentation for 
the study and samples were collected in the morning as they 
presented at the study centre set up in the village. 10 mls of  
blood was collected from each subject by venepuncture and 
then distributed into a fluoride bottle for determination of  
fasting plasma glucose, and a heparinized bottle for 
determination of  Total, HDL- and LDL-cholesterol.
Fasting plasma glucose was analysed by the glucose oxidase 
20method , total cholesterol by the cholesterol oxidase 
21 22method  and triglyceride by the lipase method .
Statistical Analysis
The results obtained were analysed using SPSS for windows 
software version 14 0 and Epi info version 6.04D and are 
expressed as mean ± SEM, percentages and tables. P values 
less than 0.05 were considered significant.
RESULTS
Age and sex Distribution of Subjects
The age and sex distribution of  the subjects is as shown in 
Table I. One hundred and forty males and 160 females 
participated in this study. The mean age of  the participants 
was 40.55±0.99 years. Seventy two of  the participants were 
farmers, 75 were students, 15 were civil servants and 38 were 
self  employed as petty traders, tailors/seamstresses.
Prevalence of Risk Factors
Abdominal Obesity
Sixteen subjects (5.33%) had large waist circumferences or 
abdominal obesity as defined by ATP diagnostic criteria 
(Table II). Of  these subjects, 12 (75.00%) were females and 4 
(25.00%) were males. Only 3 (18.80%) of  them had MS-ATP. 
The relative risk (RR) of  large waist circumference for MS-
ATP was 3.33 (95% CI: 1.08-10.26). 
Hypertension
One hundred and one of  the 300 participants (33.67%) had 
systolic hypertension as defined by ATP III (Table 2). Forty 
seven of  the participants with hypertension (46.53%) were 
males while 54 (53.46%) were females. Fourteen (13.90%) of  
these participants had MS-ATP. The relative risk (RR) of  high 
blood pressure for metabolic syndrome was 5.52 (95% CI: 
2.02-20.56).
Impaired Fasting Plasma Glucose
The prevalence of  impaired fasting blood glucose (IFPG) 
among the participants was 7.33% (22 participants); 59.09% 
(13 participants) of  these were females while 40.91% were 
males (Table 2). RR = 11.37 (95% CI: 5.72-25.03). 
Hypertriglyceridaemia
A total of  34 participants had serum triglyceride levels greater 
than or equal to 1.7 mmol/L, making the prevalence of  
hypertriglyceridaemia among the participants 11.33% 
(61.80% were females while 38.20% were males) (Table 2). 
Fourteen of  the participants with hypertriglyceridaemia had 
MS-ATP. RR=21.91 (95% CI: 8.42-57.32). 
Low Hdl-cholesterol
Two hundred and fifty seven of  the 300 subjects that 
participated in this study at Odufor had low serum HDL-
cholesterol, making the prevalence 85.67% (Table 2). One 
hundred and fifty five were females (60.30%) and 102 were 
males (39.70%). RR was not calculable as an expected cell 
had 0 value (No participant with normal HDL cholesterol 
had MS-ATP).
.
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Metabolic Syndrome as Defined by ATP III (MS-ATP)
The prevalence of  MS-ATP among the participants was 6.3% 
(Table 2). Fifty two point six three percent of  those diagnosed 
with MS-ATP (10 participants) were females or 6.25% of  the 
females that participated in the study. Forty seven point three 
seven percent of  all those diagnosed with MS-ATP (9 
participants) were males. This proportion represented 6.43% 
of  the male subjects. The average age of  all the participants 
with metabolic syndrome was 42.68±4.55 years. Thirteen 
(68.42%) of  all those with metabolic syndrome were farmers, 
4 (21.05%) were students and 2 (10.53%) were civil servants.
DISCUSSION
The main determinant of  metabolic syndrome is excess 
adiposity that often (but not always) results in insulin 
1,2,23,24resistance . We found in this study however, that the 
prevalence of  abdominal obesity (large waist circumference 
serving as proxy) was only 5.33% and that only 3 of  the 16 
participants with abdominal obesity had MS-ATP (ages 35, 
46 and 60; 1 male and 2 females). The relative risk of  
abdominal obesity for MS-ATP was 3.33 (95% CI: 1.08-
10.26), smaller than the relative risk of  the other components 
calculated. This is at variance with the findings reported by 
16 18Fezau et al and Siminialayi et al . Both studies found that 
central obesity was the most prevalent component of  the 
metabolic syndrome in Africans.
16The Fezau study  also reported that hypertriglyceridaemia 
was almost non-existent in their subjects. We however, found 
that the prevalence of  hypertriglyceridamia was 11.33%, 
third, behind low HDL-cholesterol (85.67%) and 
hypertension (33.67%) but the relative risk of  
hypertriglyceridamia for MS-ATP (table 2) was highest of  all 
the metabolic syndrome components (21.91, 95% CI: 8.42-
57.32). The Low HDL-cholesterol finding is in agreement 
18with an earlier report by Siminialayi et al . Like that study 
also, which reported the RR as insignificant for one set of  
participants and incalculable for the other, the RR of  low 
HDL-cholesterol in this study was incalculable. 
The Odufor people eat mainly carbohydrates in the form of  
cassava and yam for all three meals of  the day. They are 
however very hard working, physically exerting subsistence 
farmers, explaining the low prevalence of  obesity in the 
community. It was recently reported that the excessive intake 
of  carbohydrates and saturated fats in addition to causing 
obesity could directly induce several proinflammatory 
effects, including the increased production of  reactive oxygen 
species, upregulation of  nuclear factor ß in monocytes and 
14polymorphonuclear cells and CRP production . Also, we 
now know that apart from excess adiposity, low grade 
5-8systemic inflammation can induce insulin resistance .  
Insulin resistance is an impaired biological response to 
insulin actions in the insulin-responsive organ systems of  
25skeletal muscle, the liver and fat tissues . This means that 
muscle, fat and liver cells are less able to take up glucose from 
the blood and there is an increase in gluconeogenesis that can 
lead to increased circulating glucose concentrations and 
compensatory hyperinsulinaemia, enhanced free fatty acid 
release by fat tissue that can result in increased triglycerides 
and reduced HDL-cholesterol concentrations and protein 
15,24catabolism . This also means that recently identified 
biological actions of  insulin, including anti-inflammatory 
effects mediated by decreasing nuclear factor ß, increasing 
inhibitor of  ß, reducing reactive oxygen species, and 
circulating adhesion molecules as well as profibrinolytic 
action such as decreasing plasminogen activator inhibitor-
141production, are inhibited . Thus, insulin resistance not only 
accelerates atherogenesis through the development of  
classical metabolic risk factors but also by directly generating 
24proinflammatory and prothrombotic states .
We think the prevalence of  low HDL-cholesterol is only 
partly the consequence of  insulin resistance. The low levels of  
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HDL-cholesterol are in keeping with the findings of  the 
National Survey of  Non-communicable diseases in Nigeria 
26reported by the Federal Ministry of  Health , and the reports 
17 18of  Isezuo  and Siminialayi et al . All these reports indicate 
that Nigerians and other Africans have low levels of  total, 
LDL- and HDL-cholesterol and that low-HDL cholesterol is 
a poor indicator of  cardiovascular disease risk in Africans. 
CONCLUSION
The prevalence of  MS in Odufor Etche community is low, 
central obesity has low a prevalence rate in the community 
and a low relative risk for MS-ATP. Hypertriglyceridaemia 
appears to be associated with the greatest risk of  developing 
metabolic syndrome in this community while Low HDL-
cholesterol although most prevalent is a poor diagnostic 
requirement for metabolic syndrome. These findings 
reinforce the view already expresses that existing metabolic 
syndrome definitions need to be modified for Africans. In this 
particular community at least, central obesity is not the key 
determinant of  metabolic syndrome. We postulate that this is 
perhaps related to the fact that they eat largely carbohydrate 
based meals and are very active subsistence farmers.
REFERENCES
1. Grundy SM. Controversy in clinical endocrinology. 
Metabolic syndrome: a multiplex cardiovascular risk 
factor. J Clin Endocrinol Metab 2007; 92(2), 399-404.
2. Eckel RH, Grundy SM, Zimmet PZ. The metabolic 
syndrome. Lancet 2005; 365(9468) 1415-1428. 
3. Alberti KG, Zimmet P, Shaw J. The metabolic 
syndrome - a new worldwide definition. Lancet 2005; 
366(9491), 1059-1062. 
4. Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J. 
Rheumatoid arthritis: a disease associated with 
accelerated atherogenesis. Semin Arthritis Rheum 
2005; 35(1), 8-17. 
5. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose 
expression of  tumor necrosis factor-a: direct role in 
obesity-linked insulin resistance. Science 1993; 
259(5091), 87-91. 
6. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White 
MF, Spiegelman BM. IRS-1 mediated inhibition of  
insulin receptor tyrosine kinase activity in TNF-a- and 
obesity-induced insulin resistance. Science 1996; 
271(5249), 665-668. 
7. Rui L, Yuan M, Frantz D, Shoelson S, White MF. 
SOCS-1 and SOCS-3 block insulin signaling by 
ubiquitin-mediated degradation of  IRS1 and IRS2. J 
Biol Chem 2002; 277(44), 42394-42398. 
8. Ridker PM, Wilson PW, Grundy SM. Should C-
reactive protein be added to metabolic syndrome and to 
assessment of  global cardiovascular risk? Circulation 
2004; 109(23), 2818-2825.
9. Gabriel SE, Crowson CS, O'Fallen WM: Comorbidity 
in arthritis. J Rheumatol 1994; 26(11), 2475-2479. 
10. Del Rincon ID, Williams K, Stern MP, Freeman GL, 
Escalante A. High incidence of  cardiovascular events in 
a rheumatoid arthritis cohort not explained by 
traditional cardiac risk factors. Arthritis Rheum 2001; 
44(12), 2737-2745. 
11. Solomon DH, Karlson EW, Rimm EB et al. 
 
Cardiovascular morbidity and mortality in women 
diagnosed with rheumatoid arthritis. Circulation 
2003;107(9), 1030-1307. 
12. Wolfe F, Freundlich B, Straus WL. Increase in 
cardiovascular and cerebrovascular disease prevalence 
in rheumatoid arthritis. J Rheumatol 2003; 30(1), 36-40. 
13. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, 
Tracy RP, Haffner SM. Chronic subclinical 
inflammation as part of  the insulin resistance 
syndrome: the Insulin Resistance Atherosclerosis Study 
(IRAS). Circulation 2000; 102(1), 42-47.
14. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg 
R. Metabolic syndrome. A comprehensive perspective 
based on interactions between obesity, diabetes, and 
inflammation. Circulation 2005; 111(11), 1448-1454.
15. Gami AS, Witt BJ, Howard DE et al. Metabolic 
syndrome and risk of  incident cardiovascular events 
and death: a systematic review and meta-analysis of  
longitudinal studies. J Am Coll Cardiol 2007; 49(4), 
403-414.
16. Fezau L, Balkau B, Kegne A-P, Sobngwa E, Mbonya J-
C. Metabolic syndrome in a sub-Saharan African 
setting: central obesity may be the key determinant. 
Atherosclerosis 2007; 193(1): 70-76.
17. Isezuo SA. Is high density lipoprotein cholesterol useful 
in diagnosis of  metabolic syndrome in native Africans 
with type 2 diabetes? Ethn Dis 2005; 15: 6-10.
18. Siminialayi IM, Emem-Chioma PC, Odia OJ. Relative 
risk of  metabolic syndrome components in Nigerians: 
the adult treatment III definition. PMJ 2009; 3: 302-311.
19. Grundy SM, Cleeman JI, Daniels SR, Donato KA, 
Eckel RH, Franklin BA, Gordon DJ, et al. Diagnosis 
and management of  metabolic syndrome. Circulation 
2005; 112: 2735-2752.
20. World Health Organization (WHO). Blood safety and 
clinical technology: guidelines on standard operating 
procedures for clinical chemistry. Available at: 
http://www.searo.who.int/EN/Section10/Section17
/Section53/Section481_1753.htm Accessed March 17, 
2007.
21. Emeis JJ, van Gent CM, van Sabben CM. An enzymatic 
method for the histochemical localization of  free 
esterified cholesterol separately. The Histochem J 1977; 
9: 197-204.
22. Gibbons VB, Ballantyne FC. Triglyceride estimation in 
high density lipoproteins. Med Lab Sci 1981; 38: 277-
279.
23. Dessein PH, Gonzalez-Gay MA, Woodwiss AJ, Joffe 
BI, Norton GR, Solomon A. The impact of  metabolic 
syndrome on cardiovascular risk factors and disease in 
rheumatoid arthritis. Future Rheumatol 2008; 3(4):335-
349.
24. Grundy SM. Does a diagnosis of  metabolic syndrome 
have value in clinical practice? Am J Clin Nutr 2006; 
83(6), 1248-1251.
25. Reaven GM. Role of  insulin resistance in human 
disease. Diabetes 37(12), 1595-1607 (1988).
26. Akinkugbe OO, ed. Non-communicable diseases in 
Nigeria: final report of  a national survey. Federal 
Ministry of  Health (Nigeria) 1997; 4: 5-118.
COMPETING INTERESTS: The authors have no competing 
Siminalayi IM, Emem-Chioma PC - Metabolic Syndrome in a Rural Nigerian Community
The Nigerian Health Journal, Vol. 8, No 3 -4, July - December  2008
